stoxline Quote Chart Rank Option Currency Glossary
CEL-SCI Corporation (CVM)
1.33  -0.03 (-2.21%)    06-12 16:00
Open: 1.37
High: 1.38
Volume: 137,382
Pre. Close: 1.36
Low: 1.3
Market Cap: 72(M)
Technical analysis
2024-06-12 4:21:21 PM
Short term     
Mid term     
Targets 6-month :  2.24 1-year :  2.79
Resists First :  1.92 Second :  2.39
Pivot price 1.26
Supports First :  1.16 Second :  0.97
MAs MA(5) :  1.3 MA(20) :  1.28
MA(100) :  1.87 MA(250) :  1.9
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  70 D(3) :  60.6
RSI RSI(14): 48
52-week High :  3.23 Low :  1.03
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CVM ] has closed below upper band by 16.7%. Bollinger Bands are 67% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.38 - 1.39 1.39 - 1.39
Low: 1.28 - 1.29 1.29 - 1.3
Close: 1.31 - 1.33 1.33 - 1.33
Company Description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

Headline News

Mon, 10 Jun 2024
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor - Manchestertimes

Fri, 07 Jun 2024
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor - BioSpace

Wed, 29 May 2024
D.A. Davidson & CO. Purchases 247128 Shares of CEL-SCI Co. (NYSE:CVM) - Defense World

Thu, 16 May 2024
Cel-Sci: Fiscal Q2 Earnings Snapshot - Houston Chronicle

Thu, 09 May 2024
Cel Sci exec Patricia Prichep buys $11,120 in company stock By -

Wed, 08 May 2024
Why CEL-SCI (CVM) Shares Are Trading Higher - CEL-SCI (AMEX:CVM) - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 50 (M)
Shares Float 46 (M)
Held by Insiders 3.4 (%)
Held by Institutions 11.1 (%)
Shares Short 6,510 (K)
Shares Short P.Month 6,150 (K)
Stock Financials
EPS -0.78
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.33
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -46.2 %
Return on Equity (ttm) -126.5 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) -0.51
Sales Per Share 0
EBITDA (p.s.) -0.59
Qtrly Earnings Growth 0 %
Operating Cash Flow -23 (M)
Levered Free Cash Flow -8 (M)
Stock Valuations
PE Ratio -1.7
PEG Ratio 0
Price to Book value 4.01
Price to Sales 0
Price to Cash Flow -2.92
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android